Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether treatment with the study drug durvalumab
combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more
effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.